Literature DB >> 22072397

Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures.

Eve Donnelly1, Dennis S Meredith, Joseph T Nguyen, Brian P Gladnick, Brian J Rebolledo, Andre D Shaffer, Dean G Lorich, Joseph M Lane, Adele L Boskey.   

Abstract

Reduction of bone turnover with bisphosphonate treatment alters bone mineral and matrix properties. Our objective was to investigate the effect of bisphosphonate treatment on bone tissue properties near fragility fracture sites in the proximal femur in postmenopausal women with osteoporosis. The mineral and collagen properties of corticocancellous biopsies from the proximal femur were compared in bisphosphonate-naive (-BIS, n = 20) and bisphosphonate-treated (+BIS, n = 20, duration 7 ± 5 years) patients with intertrochanteric (IT) and subtrochanteric (ST) fractures using Fourier transform infrared imaging (FTIRI). The mean values of the FTIRI parameter distributions were similar across groups, but the widths of the parameter distributions tended to be reduced in the +BIS group relative to the -BIS group. Specifically, the widths of the cortical collagen maturity and crystallinity were reduced in the +BIS group relative to those of the -BIS group by 28% (+BIS 0.45 ± 0.18 versus -BIS 0.63 ± 0.28, p = 0.03) and 17% (+BIS 0.087 ± 0.012 versus -BIS 0.104 ± 0.036, p = 0.05), respectively. When the tissue properties were examined as a function of fracture morphology within the +BIS group, the FTIR parameters were generally similar regardless of fracture morphology. However, the cortical mineral:matrix ratio was 8% greater in tissue from patients with atypical ST fractures (n = 6) than that of patients with typical (IT or spiral ST) fractures (n = 14) (Atypical 5.6 ± 0.3 versus Typical 5.2 ± 0.5, p = 0.03). Thus, although the mean values of the FTIR properties were similar in both groups, the tissue in bisphosphonate-treated patients had a more uniform composition than that of bisphosphonate-naive patients. The observed reductions in mineral and matrix heterogeneity may diminish tissue-level toughening mechanisms.
© 2012 American Society for Bone and Mineral Research

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22072397      PMCID: PMC4404705          DOI: 10.1002/jbmr.560

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  33 in total

1.  Mineral heterogeneity affects predictions of intratrabecular stress and strain.

Authors:  G A P Renders; L Mulder; L J van Ruijven; G E J Langenbach; T M G J van Eijden
Journal:  J Biomech       Date:  2010-10-30       Impact factor: 2.712

Review 2.  Infrared analysis of bone in health and disease.

Authors:  Adele Boskey; Richard Mendelsohn
Journal:  J Biomed Opt       Date:  2005 May-Jun       Impact factor: 3.170

3.  Effects of non-enzymatic glycation on cancellous bone fragility.

Authors:  S Y Tang; U Zeenath; D Vashishth
Journal:  Bone       Date:  2006-12-21       Impact factor: 4.398

4.  Bone tissue composition varies across anatomic sites in the proximal femur and the iliac crest.

Authors:  Eve Donnelly; Dennis S Meredith; Joseph T Nguyen; Adele L Boskey
Journal:  J Orthop Res       Date:  2011-10-27       Impact factor: 3.494

5.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

6.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

7.  Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.

Authors:  Samuel Gourion-Arsiquaud; Matthew R Allen; David B Burr; Deepak Vashishth; Simon Y Tang; Adele L Boskey
Journal:  Bone       Date:  2009-11-17       Impact factor: 4.398

8.  Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.

Authors:  Matthew R Allen; David B Burr
Journal:  J Bone Miner Res       Date:  2007-11       Impact factor: 6.741

9.  Use of FTIR spectroscopic imaging to identify parameters associated with fragility fracture.

Authors:  Samuel Gourion-Arsiquaud; Dan Faibish; Elizabeth Myers; Lyudmila Spevak; Juliet Compston; Anthony Hodsman; Elizabeth Shane; Robert R Recker; Elizabeth R Boskey; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2009-09       Impact factor: 6.741

10.  Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs.

Authors:  M Saito; S Mori; T Mashiba; S Komatsubara; K Marumo
Journal:  Osteoporos Int       Date:  2008-03-29       Impact factor: 5.071

View more
  80 in total

1.  Bone: Effects of bisphosphonates on bone quality components and fracture risk.

Authors:  Nick Warde
Journal:  Nat Rev Rheumatol       Date:  2011-12-06       Impact factor: 20.543

Review 2.  Atypical femoral fractures: epidemiology, etiology, and patient management.

Authors:  Eve Donnelly; Anas Saleh; Aasis Unnanuntana; Joseph M Lane
Journal:  Curr Opin Support Palliat Care       Date:  2012-09       Impact factor: 2.302

Review 3.  The fracture mechanics of human bone: influence of disease and treatment.

Authors:  Elizabeth A Zimmermann; Björn Busse; Robert O Ritchie
Journal:  Bonekey Rep       Date:  2015-09-02

4.  Studying variations in bone composition at nano-scale resolution: a preliminary report.

Authors:  Samuel Gourion-Arsiquaud; Curtis Marcott; Qichi Hu; Adele L Boskey
Journal:  Calcif Tissue Int       Date:  2014-08-26       Impact factor: 4.333

5.  Atypical femur fracture during bisphosphonate drug holiday: a case series.

Authors:  A J Lovy; S M Koehler; A Keswani; D Joseph; R Hasija; R Ghillani
Journal:  Osteoporos Int       Date:  2015-04-02       Impact factor: 4.507

6.  Sexually Dimorphic Influence of Neonatal Antibiotics on Bone.

Authors:  Matteo M Pusceddu; Patricia J Stokes; Alice Wong; Melanie G Gareau; Damian C Genetos
Journal:  J Orthop Res       Date:  2019-07-26       Impact factor: 3.494

7.  Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?

Authors:  Adele L Boskey; Josephine Marino; Lyudmila Spevak; Nancy Pleshko; Stephen Doty; Erin M Carter; Cathleen L Raggio
Journal:  Clin Orthop Relat Res       Date:  2015-08       Impact factor: 4.176

Review 8.  Bone microdamage, remodeling and bone fragility: how much damage is too much damage?

Authors:  Zeynep Seref-Ferlengez; Oran D Kennedy; Mitchell B Schaffler
Journal:  Bonekey Rep       Date:  2015-03-18

Review 9.  Atypical femoral fractures: a review of the literature.

Authors:  Pingal A Desai; Parth A Vyas; Joseph M Lane
Journal:  Curr Osteoporos Rep       Date:  2013-09       Impact factor: 5.096

Review 10.  Bone quality: the determinants of bone strength and fragility.

Authors:  Hélder Fonseca; Daniel Moreira-Gonçalves; Hans-Joachim Appell Coriolano; José Alberto Duarte
Journal:  Sports Med       Date:  2014-01       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.